The present invention provides methods for diagnosing human hepatic disorders, such as non-alcoholic steatohepatitis (NASH), identifying a human subject at risk of an adverse drug reaction, and determining an appropriate dosage of a therapeutic drug for a human subject. The marker is an increased level of acetaminophen-glucuronide in a plasma or urine sample from a human subject.